According to GuruFocus, these stocks have reached their 52-week highs.
Mastercard reached the 52-week high of $112.47
Mastercard Inc. (MA, Financial) is a technology company in the payments industry that connects consumers, financial institutions, merchants, governments and businesses, enabling them to use electronic forms of payment instead of cash and checks. Mastercard manages several payment brands and an "open loop" global payment network, which allows it to provide authorization, clearing and settlement of electronic payment transactions. The company generates revenue by charging fees to its customers (issuers and acquirers) based on both the dollar volume of card activity and the number of transactions processed through the network.
The price of Mastercard shares has reached $112.47, which is 0.9% off the 52-week high of $113.50. Mastercard has a market cap of $121.23 billion; its shares were traded around $112.47 with a price-earnings (P/E) ratio of 30.48 and a price-sales (P/S) ratio of 11.51. The trailing 12-month dividend yield is 0.70%. The forward dividend yield is 0.78%. Mastercard had an annual average earnings growth of 17.40% over the past five years.
The company recently announced financial results for the fourth quarter and full-year 2016. The company reported net income of $933 million, an increase of 4% on a currency-neutral basis, and earnings per diluted share of 86 cents, up 7% on a currency-neutral basis from the year-ago period. Excluding a special item this quarter related to merchant litigation in the U.K., the company reported net income of $940 million, an increase of  5% on a currency-neutral basis from the same period in 2015.
CNA Financial reached the 52-week high of $44.17
CNA Financial Corp. (CNA, Financial) is an insurance holding company. The company offers commercial, property and casualty coverage, risk management, information services, warranty and claims administration. CNA Financial provides insurance and risk management services to businesses, associations and individuals. It is the eighth- largest U.S. commercial insurer and the 13th- largest U.S. property and casualty insurer, with offices throughout the United States, Canada and Europe. CNA's core business is specialty and commercial property and casualty insurance operated through CNA Specialty and CNA Commercial.
The price of CNA Financial shares has reached $44.17, which is 1.6% off the 52-week high of $44.88. The company has a market cap of $11.95 billion; its shares were traded around $44.17 with a P/E ratio of 13.98 and P/S ratio of 1.28. The trailing 12-month dividend yield is 2.26%. The forward dividend yield is 2.26%.
The company recently announced fourth-quarter 2016 net income of $241 million, or 89 cents per share, and net operating income of $221 million, or 82 cents per share. Full-year 2016 results were net income of $859 million, or $3.17 per share, and net operating income of $824 million, or $3.04 per share. Property and casualty operations combined ratios for the quarter and year were 99.9% and 95.9% respectively.
Lam Research reached the 52-week high of $128.36
Lam Research Corp. (LRCX, Financial) is a supplier of wafer fabrication equipment and services to the semiconductor industry.The company is focused on the etch market, which is a key step in the semiconductor manufacturing process. Lam's flagship Kiyo, Vector and Sabre products are sold in all major geographies to key customers such as Samsung Electronics (XKRX:005930, Financial) and Taiwan Semiconductor Manufacturing (TSM, Financial).
The price of Lam Research shares has reached $128.36, which is 0.8% off the 52-week high of $129.35. The company has a market cap of $20.9 billion; its shares were traded around $128.36 with a P/E ratio of 23.09 and P/S ratio of 3.60. The trailing 12-month dividend yield is 1.17%. The forward dividend yield is 1.40%. Lam Research had an annual average earnings growth of 11.80% over the past five years.
In fourth-quarter 2016, revenue was $1,882 million and the gross margin was $847 million, or 45.0% of revenue. Operating expenses were $407 million, the operating margin was 23.4% of revenue and net income was $333 million, or $1.81 per diluted share on a GAAP basis.
President and CEO Martin B. Anstice sold 48,000 shares of the stock on March 13 for an average price of $120.79 per share. The stock price has increased 6.27% since then.
IDEXX Laboratories reached the 52-week high of $154.61
IDEXX Laboratories Inc. (IDXX, Financial) develops, manufactures and distributes products and provides services to the veterinary, bioresearch, water, livestock, poultry and dairy markets. The company primarily develops, manufactures and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, laboratory equipment for blood-panel analysis, reference lab services and tests to detect and manage disease in livestock. Idexx generates about 42% of its revenue from outside the United States.
The price of IDEXX shares has reached $154.61, which is 0.7% off the 52-week high of $155.65. The company has a market cap of $13.59 billion; its shares were traded around $154.61 with a P/E ratio of 63.36 and P/S ratio of 7.92. Idexx Laboratories had an annual average earnings growth of 13.50% over the past 10 years.
The company recently reported revenue for the fourth quarter of 2016 of $443 million, an increase of 11% compared to the prior-year period on a reported basis and 12% on an organic basis. Fourth-quarter results were supported by accelerated gains in Companion Animal Group (CAG) Diagnostics recurring revenue and continued high growth in premium instrument placements. EPS were 58 cents for the fourth quarter, representing 21% growth year-over-year on a reported basis and 33% on a constant-currency basis.
Becton, Dickinson & Co. reached the 52-week high of $183.44
Becton, Dickinson & Co. (BDX, Financial) is a medical technology company engaged in the manufacture and sale of medical devices, instrument systems and reagents used by health care institutions, life science researchers, the general public and clinical laboratories. It is the world's largest manufacturer and distributor of medical surgical products. The company also manufactures diagnostic instruments and reagents as well as flow cytometry and cell-imaging systems. International revenue accounts for 60% of the company's business. With CareFusion, BDX has entered into medical systems (such as infusion pumps, ventilators and respirators) as well as procedural solutions businesses.
The price of shares has reached $183.44, which is 1.5% off the 52-week high of $186.11. The company has a market cap of $39.04 billion; its shares were traded around $183.44 with a P/E ratio of 30.47 and P/S ratio of 3.21. The trailing 12-month dividend yield is 1.52%. The forward dividend yield is 1.59%. The company had an annual average earnings growth of 5.60% over the past 10 years.
The company recently reported revenues of $2.922 billion for the first fiscal quarter of 2017. This represents a decrease of 2.1% from the prior-year period due to the divestiture of the Respiratory Solutions business in October 2016. On a comparable, currency-neutral basis, first-quarter revenues grew 6.1%.
Disclosure: I do not own these stocks.
Start a free 7-day trial of Premium Membership to GuruFocus.
